Related Experiment Video
Updated: Jul 4, 2026
Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats
Published on: March 28, 2025
Risk factors for severe hyperbilirubinemia among infants with borderline bilirubin levels: a nested case-control
Michael W Kuzniewicz1, Gabriel J Escobar, Soora Wi
1Division of Neonatology, University of California San Francisco, San Francisco, CA, USA.
Insights
Phototherapy effectively prevents high total serum bilirubin (TSB) levels in newborns. Key risk factors for elevated TSB include lower gestational age, bruising, and rapid TSB increase.
Area of Science:
- Neonatal Medicine
- Pediatrics
- Clinical Research
Background:
- Hyperbilirubinemia is common in newborns.
- Severe hyperbilirubinemia can lead to serious complications.
- Predicting and preventing severe hyperbilirubinemia is crucial.
Purpose of the Study:
- To evaluate the effectiveness of phototherapy in preventing severe hyperbilirubinemia (TSB ≥ 25 mg/dL).
- To identify other predictors of severe hyperbilirubinemia in infants with moderate TSB levels.
Main Methods:
- Retrospective cohort study of 285,295 infants (≥ 34 weeks gestation).
- Identified 17,986 infants with TSB 17-22.9 mg/dL at ≥ 48 hours.
- Matched cases (TSB ≥ 25 mg/dL) with controls based on phototherapy thresholds.
Main Results:
- Phototherapy was administered to 10% of cases vs. 41% of controls, showing 85% effectiveness.
- Lower gestational age (34-39 weeks), bruising, exclusive breastfeeding, and rapid TSB increase were significant predictors.
- Adjusted odds ratios indicated increased risk associated with these factors.
Conclusions:
- Phototherapy is highly effective in preventing severe hyperbilirubinemia.
- Gestational age, bruising, family history, and rapid TSB rise are key predictors.
- Early identification and intervention are vital for managing neonatal jaundice.
Objective:
To estimate the effect of phototherapy and other predictors on the risk of total serum bilirubin (TSB) >or= 25 mg/dL in infants with a TSB of 17 to 22.9 mg/dL at age >or= 48 hours.
Study Design:
From a cohort of 285295 infants >or= 34 weeks gestation and >or= 2000 g born between 1995 and 2004 in northern California Kaiser hospitals, we identified 17986 with a TSB of 17 to 22.9 mg/dL at age >or= 48 hours. All infants exhibiting a TSB >or= 25 mg/dL were selected as cases for the study. Four randomly selected controls were matched to each case based on the difference between their qualifying TSB and the American Academy of Pediatrics' phototherapy threshold.
Results:
A total of 62 cases were identified (0.4%). Six of these (10%) received inpatient phototherapy within 8 hours, along with 101 controls (41%) (adjusted odds ratio [AOR] 0.15; 95% confidence interval [CI] 0.06 to 0.40). Cases more often had lower gestational age (AOR 3.24; 95% CI 1.24 to 8.47 for 38 to 39 weeks and AOR = 3.70; 95% CI 0.61 to 22.4 for 34 to 37 weeks compared with >or= 40-week infants), bruising, (AOR 2.52; 95% CI 1.16 to 5.50), exclusive breast-feeding (AOR 2.09; 95% CI 1.05 to 4.03), and TSB increase of >or= 6 mg/dL/day (AOR 2.39; 95% CI 1.18 to 4.85).
Conclusions:
Phototherapy was 85% effective in preventing TSB >or= 25 mg/dL. The strongest predictors of TSB >or= 25 mg/dL were gestational age, bruising, family history, and rapid rise in TSB.
Related Concept Videos
01:25Jaundice
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:19Rh Blood Group